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Subarachnoid hemorrhage (SAH), a unique form of hemorrhagic stroke, remains 
a serious health problem with a 30% mortality rate in the United States. Of those 
surviving the initial hemorrhage, more than half deteriorate in the days following SAH 
due to delayed cerebral ischemia (DCI) and early brain injury (EBI). The predominant 
vascular deficit leading to EBI is blood-brain barrier (BBB) disruption, along with the 
release of cytotoxic agents and inflammatory mediators. Recently, a causal link between 
metalloprotease 9 (MMP9) and EBI after SAH has been suggested in rodent studies. 
A correlation between serum MMP9 levels and vasospasm in human SAH has also 
been noted. While a major contributing role of MMP9 in SAH-induced brain injury 
is rapidly being established, the upstream molecular events leading to its upregulation 
and the downstream molecular events by which it causes EBI are poorly understood. 
Cyclophilin A (CypA) is a proinflammatory molecule that is known to drive MMP9 
expression via the transcription factor NF-κ B p65. Previously we discovered that CypA 
plays a causal role in AD-induced cerebrovascular deficits, including APOE4-linked BBB 
disruption and CBF deficits. CypA is secreted from cells in response to inflammatory 
stimuli, such as hypoxia and oxidative stress. Whether CypA plays a role in EBI and DCI 
following SAH, however, is not known. Our key goal is to identify if CypA levels increase 
in SAH patients and are involved in DCI and EBI. We hypothesize that reactive oxygen 
species (ROS) released by hypoperfusion and the degradation of hemoglobin stimulate 
the secretion of significant amounts of CypA, which contributes to neurological and 
cerebral dysfunction. Furthermore, we hypothesize a prevalent role of CypA in DCI, 
EBI, and poor clinical outcome and therefore hope to identify CypA as a therapeutically 
targetable molecule.
